Fig. 6

A checkpoint inhibitor trial enrolled 74 patients diagnosed with advanced lung cancer. Venous blood draws were collected followed by initiation of their ICI treatment regimen. Adverse events were continuously observed; tumor responses were regularly monitored. Best radiologic response was used as the observed response for analysis in our study. The serum samples collected pretreatment were analyzed on the FSP/Antibody assays to develop models of predicted response and adverse event. NP non-progressor, P progressor, R responder, NR non-responder, Acc accuracy, Class classified